This paper discusses the effectiveness of molecular blood typing in decreasing the epidemiology of alloimmunization among TDT patients who require regular blood transfusions. The study involves 500 TDT patients based on a prospective cohort study and compares the serological typing with molecular typing within 24 months. Molecular typing was observed to lower alloimmunization incidence by 12. 4% when compared to 24. 8% in the non-molecular typed group, few transfusion reactions, and increased hemoglobin level. Molecular typing distinguished 35 clinically relevant antigens that are in contrast to 8. 3 with conventional methods. Due to initial costs, molecular typing may be initially more expensive, but its efficiency with fewer complications pays itself out in the long run. This research proves that molecular blood typing increases transfusion safety and improves patients’ quality of life for TDT patients and thus call for further large-scale, longitudinal study.